Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Pineocytoma is the least aggressive form of pineal parenchymal tumors, manifesting with symptoms such as Parinaud's syndrome (a group of eye movement abnormalities and pupil dysfunction, including deficiency in upward-gaze and convergence-retraction nystagmus), headaches, balance impairment, urinary incontinence, and changes in mood and that are not known to disseminate in a diffuse manner. They are usually associated with a good prognosis.
Biomarker and diagnostic research for pineocytoma has been reported in the published literature.
1 clinical trial registered. Interventions under study include drug therapy. Pipeline includes 1 PHASE1. Research is primarily industry-sponsored.
24 publications have been identified in PubMed for pineocytoma. Research spans Review / Meta-Analysis (33%), Case Report / Case Series (33%), and Clinical Trial Publication (17%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 8 | 33% |
Data assembled from 4 of 12 sources · Last updated Sep 18, 2026, 7:15 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Patient case studies |
8 |
33% |
Clinical study results | 4 | 17% |
Laboratory research | 2 | 8% |
Other research | 1 | 4% |
Testing and diagnosis research | 1 | 4% |
Vitulli F (2026). [PMID: 41832330](https://pubmed.ncbi.nlm.nih.gov/41832330/). *Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery*. [Case Report / Case Series]
Pasquinelli E (2026). [PMID: 42058762](https://pubmed.ncbi.nlm.nih.gov/42058762/). *Neurooncol Adv*. [Review / Meta-Analysis]
Mottolese C (2026). [PMID: 42115468](https://pubmed.ncbi.nlm.nih.gov/42115468/). *Adv Tech Stand Neurosurg*. [Review / Meta-Analysis]
Mottolese C (2026). [PMID: 42115457](https://pubmed.ncbi.nlm.nih.gov/42115457/). *Adv Tech Stand Neurosurg*. [Review / Meta-Analysis]
Ferreira L (2026). [PMID: 41764803](https://pubmed.ncbi.nlm.nih.gov/41764803/). *Cancer genetics*. [Case Report / Case Series]
Vasiljevic A (2026). [PMID: 42115456](https://pubmed.ncbi.nlm.nih.gov/42115456/). *Adv Tech Stand Neurosurg*. [Review / Meta-Analysis]
Tanguy R (2026). [PMID: 42115465](https://pubmed.ncbi.nlm.nih.gov/42115465/). *Adv Tech Stand Neurosurg*. [Review / Meta-Analysis]
Li B (2025). [PMID: 40117223](https://pubmed.ncbi.nlm.nih.gov/40117223/). *The American journal of case reports*. [Diagnostic / Biomarker]
Marčinković P (2025). [PMID: 40585941](https://pubmed.ncbi.nlm.nih.gov/40585941/). *Journal of surgical case reports*. [Case Report / Case Series]
Khaled H (2025). [PMID: 41353556](https://pubmed.ncbi.nlm.nih.gov/41353556/). *BMC cancer*. [Other]